Brian Cordery, a partner at Bristows who led the external legal team for Novartis
22 September 2026NewsPharmaMarisa Woutersen

Behind the case: How Novartis defended its blockbuster Entresto in the UK

After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
20 November 2026   A US patent board finds two Halozyme patents unpatentable, while a German appeals court overturns an injunction blocking the subcutaneous version of Keytruda, marking two setbacks for Halozyme in its ongoing dispute with the pharma giant.
Pharma
18 November 2026   A heated dispute over Boehringer’s diabetes drug empagliflozin has ended in a split decision, with the judge drawing a sharp line between what a patent discloses and what can be inferred from it.
Pharma
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.